NCT05461378View on ClinicalTrials.gov

PREP (Pre-Exposure Prophylaxis) of COVID-19

CompletedOBSERVATIONAL

Enrollment

138

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

January 29, 2024

Study Completion Date

January 29, 2024

Conditions

Immuno-DeficiencyCOVID-19

Interventions

DRUG

Evusheld

Participants who have received or plan to receive Evusheld.

Trial Locations (1)

15213

UPMC, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Ghady Haidar

OTHER